Denali Therapeutics (NASDAQ:DNLI) Insider Sells $284,097.00 in Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) insider Alexander Schuth sold 17,218 shares of the stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total value of $284,097.00. Following the sale, the insider owned 282,828 shares in the company, valued at approximately $4,666,662. This trade represents a 5.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Denali Therapeutics Trading Up 0.1%

Shares of DNLI opened at $17.08 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.79 and a current ratio of 9.79. The company has a market cap of $2.50 billion, a price-to-earnings ratio of -5.87 and a beta of 1.05. The stock has a fifty day moving average price of $17.35 and a two-hundred day moving average price of $15.67. Denali Therapeutics Inc. has a 52-week low of $10.57 and a 52-week high of $24.34.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, November 6th. The company reported ($0.74) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.02. During the same period last year, the business earned ($0.63) earnings per share. Denali Therapeutics’s revenue for the quarter was up .0% on a year-over-year basis. Analysts predict that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on DNLI. JPMorgan Chase & Co. boosted their target price on shares of Denali Therapeutics from $24.00 to $26.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Stifel Nicolaus set a $37.00 price objective on shares of Denali Therapeutics in a research report on Monday, November 17th. Morgan Stanley reiterated an “overweight” rating and issued a $40.00 price objective on shares of Denali Therapeutics in a research report on Thursday. BTIG Research reissued a “buy” rating and issued a $32.00 target price on shares of Denali Therapeutics in a research note on Friday, December 5th. Finally, UBS Group started coverage on Denali Therapeutics in a research report on Wednesday. They set a “buy” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $32.77.

Institutional Trading of Denali Therapeutics

Institutional investors have recently bought and sold shares of the business. Headlands Technologies LLC acquired a new position in shares of Denali Therapeutics in the 2nd quarter valued at $26,000. Johnson Financial Group Inc. acquired a new stake in shares of Denali Therapeutics during the third quarter worth $29,000. State of Wyoming acquired a new position in Denali Therapeutics in the second quarter valued at about $29,000. Quarry LP bought a new position in Denali Therapeutics during the third quarter worth about $64,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Denali Therapeutics by 15.5% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,612 shares of the company’s stock worth $79,000 after buying an additional 753 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.